267 related articles for article (PubMed ID: 35899490)
1. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
Björnsson ES; Stephens C; Atallah E; Robles-Diaz M; Alvarez-Alvarez I; Gerbes A; Weber S; Stirnimann G; Kullak-Ublick G; Cortez-Pinto H; Grove JI; Lucena MI; Andrade RJ; Aithal GP
Liver Int; 2023 Jan; 43(1):115-126. PubMed ID: 35899490
[TBL] [Abstract][Full Text] [Related]
2. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.
Björnsson ES; Bergmann OM; Björnsson HK; Kvaran RB; Olafsson S
Gastroenterology; 2013 Jun; 144(7):1419-25, 1425.e1-3; quiz e19-20. PubMed ID: 23419359
[TBL] [Abstract][Full Text] [Related]
3. Amoxicillin-Clavulanate-Induced Liver Injury.
deLemos AS; Ghabril M; Rockey DC; Gu J; Barnhart HX; Fontana RJ; Kleiner DE; Bonkovsky HL;
Dig Dis Sci; 2016 Aug; 61(8):2406-2416. PubMed ID: 27003146
[TBL] [Abstract][Full Text] [Related]
4. Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries.
Bessone F; Ferrari A; Hernandez N; Mendizabal M; Ridruejo E; Zerega A; Tanno F; Reggiardo MV; Vorobioff J; Tanno H; Arrese M; Nunes V; Tagle M; Medina-Caliz I; Robles-Diaz M; Niu H; Alvarez-Alvarez I; Stephens C; Lucena MI; Andrade RJ
Arch Toxicol; 2023 Feb; 97(2):593-602. PubMed ID: 36416910
[TBL] [Abstract][Full Text] [Related]
5. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.
Chalasani N; Bonkovsky HL; Fontana R; Lee W; Stolz A; Talwalkar J; Reddy KR; Watkins PB; Navarro V; Barnhart H; Gu J; Serrano J;
Gastroenterology; 2015 Jun; 148(7):1340-52.e7. PubMed ID: 25754159
[TBL] [Abstract][Full Text] [Related]
6. Risk of drug-induced liver injury from tumor necrosis factor antagonists.
Björnsson ES; Gunnarsson BI; Gröndal G; Jonasson JG; Einarsdottir R; Ludviksson BR; Gudbjörnsson B; Olafsson S
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):602-8. PubMed ID: 25131534
[TBL] [Abstract][Full Text] [Related]
7. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury.
de Boer YS; Kosinski AS; Urban TJ; Zhao Z; Long N; Chalasani N; Kleiner DE; Hoofnagle JH;
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):103-112.e2. PubMed ID: 27311619
[TBL] [Abstract][Full Text] [Related]
8. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
Chalasani N; Li YJ; Dellinger A; Navarro V; Bonkovsky H; Fontana RJ; Gu J; Barnhart H; Phillips E; Lammert C; Schwantes-An TH; Nicoletti P; Kleiner DE; Hoofnagle JH;
J Hepatol; 2023 Feb; 78(2):293-300. PubMed ID: 36152763
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
Stephens C; Robles-Diaz M; Medina-Caliz I; Garcia-Cortes M; Ortega-Alonso A; Sanabria-Cabrera J; Gonzalez-Jimenez A; Alvarez-Alvarez I; Slim M; Jimenez-Perez M; Gonzalez-Grande R; Fernández MC; Casado M; Soriano G; Román E; Hallal H; Romero-Gomez M; Castiella A; Conde I; Prieto M; Moreno-Planas JM; Giraldez A; Moreno-Sanfiel JM; Kaplowitz N; Lucena MI; Andrade RJ;
J Hepatol; 2021 Jul; 75(1):86-97. PubMed ID: 33539847
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries.
García-Cortés M; Ortega-Alonso A; Matilla-Cabello G; Medina-Cáliz I; Castiella A; Conde I; Bonilla-Toyos E; Pinazo-Bandera J; Hernández N; Tagle M; Nunes V; Parana R; Bessone F; Kaplowitz N; Lucena MI; Alvarez-Alvarez I; Robles-Díaz M; Andrade RJ
Liver Int; 2023 Aug; 43(8):1749-1760. PubMed ID: 37269163
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced liver injury.
Leise MD; Poterucha JJ; Talwalkar JA
Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
[TBL] [Abstract][Full Text] [Related]
12. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry.
Medina-Caliz I; Garcia-Cortes M; Gonzalez-Jimenez A; Cabello MR; Robles-Diaz M; Sanabria-Cabrera J; Sanjuan-Jimenez R; Ortega-Alonso A; García-Muñoz B; Moreno I; Jimenez-Perez M; Fernandez MC; Ginés P; Prieto M; Conde I; Hallal H; Soriano G; Roman E; Castiella A; Blanco-Reina E; Montes MR; Quiros-Cano M; Martin-Reyes F; Lucena MI; Andrade RJ;
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1495-1502. PubMed ID: 29307848
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China.
Shen T; Liu Y; Shang J; Xie Q; Li J; Yan M; Xu J; Niu J; Liu J; Watkins PB; Aithal GP; Andrade RJ; Dou X; Yao L; Lv F; Wang Q; Li Y; Zhou X; Zhang Y; Zong P; Wan B; Zou Z; Yang D; Nie Y; Li D; Wang Y; Han X; Zhuang H; Mao Y; Chen C
Gastroenterology; 2019 Jun; 156(8):2230-2241.e11. PubMed ID: 30742832
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements.
Nash E; Sabih AH; Chetwood J; Wood G; Pandya K; Yip T; Majumdar A; McCaughan GW; Strasser SI; Liu K
Med J Aust; 2021 Sep; 215(6):261-268. PubMed ID: 34272737
[TBL] [Abstract][Full Text] [Related]
15. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis.
Lucena MI; Kaplowitz N; Hallal H; Castiella A; García-Bengoechea M; Otazua P; Berenguer M; Fernandez MC; Planas R; Andrade RJ
J Hepatol; 2011 Oct; 55(4):820-7. PubMed ID: 21338638
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience.
Ghabril M; Fontana R; Rockey D; Jiezhun G; Chalasani N
J Clin Gastroenterol; 2013 Jul; 47(6):553-8. PubMed ID: 23388845
[TBL] [Abstract][Full Text] [Related]
17. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports.
Björnsson ES; Medina-Caliz I; Andrade RJ; Lucena MI
Hepatol Commun; 2022 Aug; 6(8):1895-1909. PubMed ID: 35596597
[TBL] [Abstract][Full Text] [Related]
18. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
Teschke R
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
[TBL] [Abstract][Full Text] [Related]
19. Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries.
Medina-Cáliz I; Sanabria-Cabrera J; Villanueva-Paz M; Aukštikalnė L; Stephens C; Robles-Díaz M; Pinazo-Bandera JM; García-Cortes M; Conde I; Soriano G; Bessone F; Hernandez N; Nunes V; Paraná R; Lucena MI; Andrade RJ; Niu H; Alvarez-Alvarez I
Arch Toxicol; 2024 Jan; 98(1):303-325. PubMed ID: 38051367
[TBL] [Abstract][Full Text] [Related]
20. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
Andrade RJ; Aithal GP; de Boer YS; Liberal R; Gerbes A; Regev A; Terziroli Beretta-Piccoli B; Schramm C; Kleiner DE; De Martin E; Kullak-Ublick GA; Stirnimann G; Devarbhavi H; Vierling JM; Manns MP; Sebode M; Londoño MC; Avigan M; Robles-Diaz M; García-Cortes M; Atallah E; Heneghan M; Chalasani N; Trivedi PJ; Hayashi PH; Taubert R; Fontana RJ; Weber S; Oo YH; Zen Y; Licata A; Lucena MI; Mieli-Vergani G; Vergani D; Björnsson ES;
J Hepatol; 2023 Sep; 79(3):853-866. PubMed ID: 37164270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
